Formulation Development
Sangamo Receives FDA Fast Track Designation for Fabry Disease Gene Therapy Product Candidate
Sangamo Therapeutics, Inc. recently announced the US FDA has granted Fast Track Designation to isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate…
Cell & Gene Therapy CDMO Targets North American Growth With Major US Acquisition
uBriGene is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from NASDAQ-listed company Mustang Bio, Inc. The cell & gene therapy (CGT) CDMO has an….
BD Launches World's First Spectral Cell Sorter With High-Speed Cell Imaging
BD (Becton, Dickinson and Company) recently announced the worldwide commercial launch of a new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to…
Biodexa Pharmaceuticals Enters Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
Biodexa Pharmaceuticals recently announced it has signed non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, Inc., a private US precision oncology company developing….
Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy for Cancer
Novel approach combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single transformative modality….
Sania Therapeutics Launches to Advance Novel Medicines for Neural Circuit Dysfunction
Sania Therapeutics, focused on developing genetic medicines for neural circuit dysfunction, recently launched by unveiling its suite of proprietary patented platforms at….
Elevar Therapeutics Submits NDA to FDA for Combination of Rivoceranib & Camrelizumab as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma
Elevar Therapeutics, Inc. recently announced it submitted an NDA to the US FDA for its investigational drug rivoceranib, an oral TKI, in combination with camrelizumab,…
Alliance Pharma & Drug Development Solutions Are Now Resolian
Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in…
Experic Adds Spray Drying Capabilities to Enhance Pharmaceutical Formulation & Development Services
Experic recently announced the addition of spray drying capabilities to support the formulation and development of biopharmaceuticals. The new spray drying services will be….
Bayer Receives Fast Track Designation for Asundexian Atrial Fibrillation Program
Bayer recently announced the US FDA has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and…
QSAM Biosciences & RLS Announce Clinical & Commercial Supply Agreement for Promising Clinical-Stage Metastatic & Primary Bone Cancer Treatment
QSAM Biosciences, Inc. and RLS (USA) Inc. recently announced a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam (Samarium-153…
NurExone Granted US Patent for Technology & Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries
NurExone Biologic Inc. recently announced it has received an issue notification from the United States Patent and Trademark Office (USPTO) for US Patent NO. 11,648,260, granted for the period of 20 years from filing date until….
APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System
Particle Works is thrilled to announce the launch of a new Application Note that delves into the advancement of nanoparticles as carriers for targeted drug delivery. Developing nanoparticles for this purpose can be….
TILT Biotherapeutics Announces First Patient Dosed in Phase 1 Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination With Checkpoint Inhibitor
TILT Biotherapeutics recently announced the first patient has been dosed in a Phase 1 trial of the company’s oncolytic adenovirus TILT-123. The multi-centre open-label, Phase…
Empty Capsules Market is Expected to Reach $4.9 Billion
The empty capsules industry is poised for significant growth in the near future. With the rising demand for pharmaceutical and nutraceutical products, the market for…
First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
First Wave BioPharma, Inc. recently announced it has completed patient screening in its ongoing Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery…
SERB Pharmaceuticals & SFJ Pharmaceuticals Announce US Partnership for Ticagrelor Reversal Agent
SERB Pharmaceuticals and SFJ Pharmaceuticals recently announced SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ. Bentracimab is a novel,…
Cellular Origins Partners With ScaleReady to Simplify, Standardize & Automate Cell Therapy Manufacturing
Cellular Origins recently announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf that brings together process development expertise, tools, and technologies for scalable CGT….
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability With CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
Olema Pharmaceuticals, Inc. recently announced interim results from an ongoing Phase 1b/2 clinical study of OP-1250, the company’s complete estrogen receptor (ER) antagonist (CERAN) and…
Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering
New collaboration combines Mekonos’ novel ex vivo delivery platform with bit.bio’s unique opti-ox™ precision cellular reprogramming technology to accelerate the development of human cells for research, drug discovery and….
